Regarding DKD patients in the CREDENCE study, reduction of risk for renal composite outcome with canagliflozin was also apparent in subgroups of patients with well-controlled diabetes, suggesting the effect of SGLT2 inhibitors on kidney function is unlikely to be mediated by further improvement of glycemic control62. This evidence concerns the gene SLC5A2 and diabetes mellitus.